News & Events

World leading manufacturer of recombinant human albumin

  • Contact
  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog
Albumedix Media News & Events CORONAVIRUS PREPAREDNESS AND BUSINESS CONTINUITY STATEMENT

CORONAVIRUS PREPAREDNESS AND BUSINESS CONTINUITY STATEMENT

19 Mar 2020

As a global provider of recombinant human albumin for the life science industry, Albumedix are fully dedicated to ensuring a stable product supply to our customers in all regions of the world. As such, we are actively monitoring and responding to the potential impact of the Coronavirus disease (COVID-19) outbreak. 

We are working diligently to ensure minimal disruption to our supply chain, whilst keeping our employees and customers safety our top priority. This statement aims to provide an insight into the measures taken at Albumedix to minimise supply chain impact.

Situation and response

Similar to most regions of the world, the United Kingdom is currently experiencing rising occurrences of COVID-19. This has now been classed as a pandemic by the WHO. Whilst the UK Government has introduced a number of actions to contain the spread of the virus it is highly likely that the peak has not yet been reached. We are following guidelines provided by WHO, CDC and the UK government, whom have all issued recommendations on how to limit the spread and impact of COVID-19. Albumedix continues to monitor the situation closely and has introduced a number of actions and guidelines to try and minimise safety risks and ensure continuity of supply to our customers, in addition to our normal high standards.

People: All staff are being encouraged to keep their distance from each other & work from home wherever possible to reduce the risk of spreading of the virus. In addition, as per UK Government guidelines any employee showing any symptoms will be encouraged to self-isolate. If an employee contracts the virus a plan is in place to ensure all contacts are identified and appropriate isolations are taken.

Travel: A ban to all business travel has been implemented. This will be reviewed as the situation develops. 

Visitors & Meetings: Only business critical visitors are being permitted on Albumedix sites. Checks are in place to ensure as far as practically possible that they have not visited or been in contact with people from at risk areas. Customer audits are being conducted where business critical, however we ask that where possible these are postponed. Similarly, we are asking our employees to postpone or convert all nonessential physical meetings to virtual meetings.

Raw Materials & Supply Chain: A dedicated task force has been established to continuously monitor our supply situation. Measures are taken to maintaining adequate raw material safety stock levels and we are working closely with our subcontractors, primary and secondary suppliers and global logistics providers to limit any supply chain impact. There is currently no evidence to support transmission of Covid-19 associated with imported goods and as a consequence no additional sanitisation protocols for the handling of our products are required.

Despite the uncertainty, we are confident that our planning means customers will continue to receive a high standard of service from us. As of now, we have not experienced any availability issues for our products. We will endeavour to update this communication with any significant changes as events unfold.

On behalf of Albumedix, we thank you for your patience and corporation as we work through these troubled times.

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix’ solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more